scholarly journals New Directions in Therapeutic Angiogenesis and Arteriogenesis in Peripheral Arterial Disease

2021 ◽  
Vol 128 (12) ◽  
pp. 1944-1957 ◽  
Author(s):  
Brian H. Annex ◽  
John P. Cooke

The prevalence of peripheral arterial disease (PAD) in the United States exceeds 10 million people, and PAD is a significant cause of morbidity and mortality across the globe. PAD is typically caused by atherosclerotic obstructions in the large arteries to the leg(s). The most common clinical consequences of PAD include pain on walking (claudication), impaired functional capacity, pain at rest, and loss of tissue integrity in the distal limbs that may lead to lower extremity amputation. Patients with PAD also have higher than expected rates of myocardial infarction, stroke, and cardiovascular death. Despite advances in surgical and endovascular procedures, revascularization procedures may be suboptimal in relieving symptoms, and some patients with PAD cannot be treated because of comorbid conditions. In some cases, relieving obstructive disease in the large conduit arteries does not assure complete limb salvage because of severe microvascular disease. Despite several decades of investigational efforts, medical therapies to improve perfusion to the distal limb are of limited benefit. Whereas recent studies of anticoagulant (eg, rivaroxaban) and intensive lipid lowering (such as PCSK9 [proprotein convertase subtilisin/kexin type 9] inhibitors) have reduced major cardiovascular and limb events in PAD populations, chronic ischemia of the limb remains largely resistant to medical therapy. Experimental approaches to improve limb outcomes have included the administration of angiogenic cytokines (either as recombinant protein or as gene therapy) as well as cell therapy. Although early angiogenesis and cell therapy studies were promising, these studies lacked sufficient control groups and larger randomized clinical trials have yet to achieve significant benefit. This review will focus on what has been learned to advance medical revascularization for PAD and how that information might lead to novel approaches for therapeutic angiogenesis and arteriogenesis for PAD.

1997 ◽  
Vol 2 (3) ◽  
pp. 243-251 ◽  
Author(s):  
Alan T Hirsch ◽  
Diane Treat-Jacobson ◽  
Harry A Lando ◽  
Dorothy K Hatsukami

Despite the widely held belief that there are no effective medical therapies for peripheral arterial disease (PAD), current data suggest that medical therapies can effectively modify the natural history of atherosclerotic lower extremity arterial occlusive disease. The ideal medical therapy would improve claudication, forestall the onset of limb-threatening events, decrease rates of invasive interventional therapies and improve long-term patient survival. These ideal outcomes might be achieved through the use of smoking cessation interventions, including behavioral and pharmacological therapy, and the administration of antiplatelet and lipid-lowering medications in patients with PAD.


Author(s):  
Craig J. Bennetts ◽  
Ahmet Erdemir ◽  
Melissa Young

Peripheral arterial disease (PAD), resulting from the accumulation of plaque, causes obstruction of blood flow in the large arteries in the arm and leg. In the United States, approximately 8.4 million people over the age of 40 have PAD [1]. If not treated, PAD can cause ischemic ulcerations and gangrene, which could eventually lead to amputation. Approximately, 25% of patients with PAD have worsening limb symptoms over 5 years, 7% requiring revascularization, and 4% requiring amputation [2].


2005 ◽  
Vol 80 (4) ◽  
pp. 494-498 ◽  
Author(s):  
Daniel G. Federman ◽  
Dana C. Ranani ◽  
Robert S. Kirsner ◽  
Dawn M. Bravata

Sign in / Sign up

Export Citation Format

Share Document